Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The substance ingenol mebutate (IM) is registered in Switzerland and many countries worldwide
for the treatment of actinic keratosis (AK). There is no data on the use of IM in organ
transplant recipients, a population highly affected by AK and skin cancer at large. The
investigators want to study the use of IM against AK in this high-risk group of patients and
assess its safety. The investigators are hoping to prove that IM is safe to use in AK of
organ transplant recipients, allowing its use in the clinical routine treatement of AK also
in this subset of patients with AK.